Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE1

Conditions

Anatomic Stage IV Breast Cancer AJCC v8 · Clinical Stage IV Cutaneous Melanoma AJCC v8 · Locally Advanced Cutaneous Melanoma · Locally Advanced Mucosal Melanoma · Metastatic Acral Melanoma · Metastatic Conjunctival Melanoma · Metastatic Cutaneous Melanoma · Metastatic HER2-Negative Breast Carcinoma · Metastatic Hormone Receptor-Positive Breast Carcinoma · Metastatic Lung Non-Small Cell Carcinoma · Metastatic Malignant Solid Neoplasm · Metastatic Mucosal Melanoma · Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 · Pathologic Stage IIID Cutaneous Melanoma AJCC v8 · Recurrent Cutaneous Melanoma · Recurrent HER2-Negative Breast Carcinoma · Recurrent Hormone Receptor-Positive Breast Carcinoma · Recurrent Lung Non-Small Cell Carcinoma · Recurrent Mucosal Melanoma · Stage III Lung Cancer AJCC v8 · Stage IV Lung Cancer AJCC v8 · Unresectable Acral Melanoma · Unresectable Cutaneous Melanoma · Unresectable Lung Non-Small Cell Carcinoma · Unresectable Mucosal Melanoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

    Contact: Study coordinator (FHCC Intake) · hutchdoc@fredhutch.org · 206-606-1024
    Contact: Principal Investigator (Joshua Veatch)
Study leads
  • Joshua Veatch

    Principal Investigator

    Fred Hutch/University of Washington Cancer Consortium